1O'Connele LL,Bennett MW,O'Sullivan GC,et al.The Fascounter attack: cancer as a site of immuneprivilege.Immunol Today,1999,20(1):46-52.
2Shin MS,Kim HS,Lee SH,et al.Alterations of Fas-pathway genes associated with nodal metastasis in non-small cell lung cancer.Oncogene,2002,21(26):4129-4136.
3Bernstorff WV,Spamjaard RA,Chan AK,et al.Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas(Apo-1/CD95) recepors and sberrant expression of functional Fas ligand.Surgery,1999,125(1):73-84.
4Bennett MW,O'Connele LL,O'Sullivan GC,et al.The Fascounter attack in vivo:apoptotic depletion of tumor infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.J Immunol,1998,160(11):5669-5675.
5Arai H,Chan SY,Bishop DK,et al.Inhibition of the alloantibody response by CD95 ligand.Nat Med,1997,3(8):843-848.
7Cho D,Song H,Kim YM,et al.Endogenous interleukin-18 modulates immune escape of murine melanoma cells by regulating the expression of Fas ligand and reactive oxygen intermediates.Cancer Res,2000,60(10):2703-2709.
8Viard-Leveugle I,Veyrenc S,French LE.Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma.J Pathol,2003,201(2):268-277.
9Dong Xilin,Dong Lei,Li Xiuxia,et al.The expression and Clinical Significance of Fas and FasL in Lung Cancer.J Med University,2003,17(3):122-128.
10Odoux C,Albers A,Amoscato AA,et al.TRAIL,FasL and a blocking anti-DR5 antibody augment paclitaxel-induced apoptosis in human non-small-cell lung cancer.Int J Cancer,2002,97(4):458-465.
4Viard-Leveugle I, Veyrenc S,French LE,et al. Frequent loss of Fas expression and function in human lung tumours with over expression of FasL in small cell lung carcinoma [J]. Pathol,2003,201(2):268-277.
5Maher S,Toomey D, Condron C,et al. Activation induced cell death: thecontroversial role of Fas and Fas ligand in immune privilege and turnout conterattack[J]. Immunol Cell Biol,2002,80(2):131-137.
6Shin MS, Kim HS, Lee SH, et al. Alterations of Fas pathway genes associated with nodal metastasis in non small cell lung cancer[J]. Oncogene, 2002,21 (26) :4129-4136.
7Liu K,Scott I, Abrams SI, et al. Alterations in Fas expression are characteristic of, but not solely responsible for enhanced metastatic competence[J]. Immunol, 2003,170(12) : 5973-5978.
8Pluygers E, Sadowska A,Chyczewski L, et al. The impact of immune response on lung cancer and the development of new treatment modalities[J]. Lung Cancer,2001,34(Suppl2) :71-77.
9Cho D, Song H, Kim YM, et al. Endogenous interleukin 18 modulates immune escape of murine melanoma cells by regulating the expression of Fas ligand and reactive oxygen intermediates[J].Cancer Res,2000,60(10):2703-2709.
10Raez LE, Cassileth PA,Schlesselman JJ ,et al. Allogeneic vaccination with a BT. 1 HLA-A gene-modified adenoeareinoma cell line in patients with advanced non-small-cell lung cancer[J].Clin Oncol,2004,22(14):2800-2807.
